Company Poolbeg Pharma PLC

Stocks

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:19 21/07/2026 pm IST			5-day change	1st Jan Change
6.200 ^GBX	+0.65%		+2.48%	+55.00%

03:25pm	Israeli Patent Office Allows Poolbeg Pharma's Application for Cytokine Release Syndrome Therapy	MT
12:35pm	Poolbeg Pharma Receives Notice Of Allowance For POLB 001 Cancer Immunotherapy-Induced CRS Patent In Israel	CI

Business description: Poolbeg Pharma PLC

Poolbeg Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. It uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.

Number of employees: 15

Sales by Activity: Poolbeg Pharma PLC

Fiscal Period: December	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)	2025 (GBP)

See all business segments

Geographical breakdown of sales: Poolbeg Pharma PLC

Fiscal Period: December	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)	2025 (GBP)

See all geographic segments

Executive Committee: Poolbeg Pharma PLC

Manager	Title	Age	Since
Jeremy Skillington CEO	Chief Executive Officer	55	01/05/2021
Ian O'Connell DFI	Director of Finance/CFO	39	01/01/2021
Meena Arora CTO	Chief Tech/Sci/R&D Officer	-	01/10/2025
Carol Dalton IRC	Investor Relations Contact	-	01/01/2021
Bruno Speder LAW	General Counsel	-	01/07/2022

See POOLBEG PHARMA PLC governance

Composition of the Board of Directors: Poolbeg Pharma PLC

Director	Title	Age	Since
Cathal Friel CHM	Chairman	62	01/09/2020
Ian O'Connell BRD	Director/Board Member	39	20/05/2021
Jeremy Skillington BRD	Director/Board Member	55	19/07/2021
Edward Gibson BRD	Director/Board Member	53	01/07/2021
Luke O'Neill BRD	Director/Board Member	62	19/07/2021
Brendan Buckley BRD	Director/Board Member	76	24/05/2023

Composition of the Board of Directors

Shareholders: Poolbeg Pharma PLC

Name	Stocks	%	Valuation
Cathal Friel 5.823 %	4,10,56,982	5.823 %	4 M p
Schroder Investment Management Ltd. 3.545 %	2,49,94,777	3.545 %	2 M p
IG Markets Ltd. 3.433 %	2,42,04,000	3.433 %	2 M p
Hargreaves Lansdown Fund Managers Ltd. 3.175 %	2,23,85,000	3.175 %	2 M p
Dominion Fiduciary Holdings Ltd. 1.219 %	85,97,794	1.219 %	781 711 p

List of POOLBEG PHARMA PLC shareholders

Company details: Poolbeg Pharma PLC

Poolbeg Pharma Plc

The Clubhouse Holborn

EC4A 3AG, London

http://www.poolbegpharma.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
POOLBEG PHARMA PLC	+0.65%	+2.48%	+100.00%	-15.65%	5.83Cr
ARGENX SE	+0.88%	-0.13%	+57.39%	+54.58%	5.38TCr
WUXI APPTEC CO., LTD.	+1.80%	+5.16%	+53.09%	+86.95%	5.47TCr
INSMED INCORPORATED	+0.82%	-2.05%	+4.93%	+411.62%	2.32TCr
BIONTECH SE	+0.34%	+2.43%	-14.98%	-14.73%	2.33TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.46%	+4.02%	+35.97%	-4.03%	2TCr
GENMAB A/S	+0.30%	-0.40%	+33.13%	-33.46%	1.73TCr
PHARMAESSENTIA CORPORATION	0.00%	-6.00%	+163.95%	+284.69%	1.5TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.49%	+1.49%	+31.63%	+654.98%	1.54TCr
EXELIXIS, INC.	+0.75%	+0.39%	+26.49%	+184.33%	1.4TCr
Average	+0.84%	-2.86%	+49.16%	+160.93%	2.37TCr
Weighted average by Cap.	+1.00%	-1.78%	+43.81%	+140.02%